share_log

Dyne Therapeutics Announces Initiation Of Phase 1/2 ACHIEVE Clinical Trial Of DYNE-101 For The Treatment of Myotonic Dystrophy Type 1

Benzinga Real-time News ·  Sep 6, 2022 07:04
Dyne Therapeutics Announces Initiation Of Phase 1/2 ACHIEVE Clinical Trial Of DYNE-101 For The Treatment of Myotonic Dystrophy Type 1
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment